Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Accured Expenses data on file, last reported at -$57.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 18.75% year-over-year to -$57.0 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a 56.57% decrease from a year earlier, with the FY2025 full-year figure at $24.0 million, down 48.94% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$57.0 million, down from $37.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for RARE reached as high as $57.4 million in Q2 2022 and fell as low as -$57.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $5.5 million across 5 years, with a median of $11.2 million in 2022.
• Across the five-year window, Change in Accured Expenses jumped 375.52% in 2022 and sank 140.02% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $27.4 million in 2022, then tumbled by 44.49% to $15.2 million in 2023, then soared by 204.72% to $46.4 million in 2024, then slipped by 20.22% to $37.0 million in 2025, then slumped by 254.0% to -$57.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$57.0 million in Q1 2026, $37.0 million in Q4 2025, and $45.1 million in Q3 2025.